PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covid-19 solutions, such as PCLMD nCoV one step RT-PCR, PCL COVID19 speed RTPCR, PCLMD ABC multi RTPCR molecular diagnostic kits; PCL COVID19 Ag rapid FIA, and PCL COVID19 Ag gold antigen diagnostic kits; and PCL COVID19 IgG/IgM rapid gold, and PCL COVID19 total Ab EIA antibody diagnostic kits. PCL, Inc. was incorporated in 2008 and is headquartered in Seoul, South Korea.
तुलना करने के लिए मीट्रिक्स | 241820 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध241820पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.3x | −2.1x | −0.5x | |
PEG अनुपात | 0.00 | −0.34 | 0.00 | |
क़ीमत/बुक | 2.5x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 14.3x | 3.8x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 53.5% | 52.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.1% | 7.6% | अनलॉक करें |